July 20, 2026 article Open access IgA nephropathy management: what does the future hold? Kidney International Supplements DOI: 10.1016/j.kisu.2026.01.001 Full text (OA) OpenAlex Authors 0 Author list not loaded yet. Cited by 0 stored of 2 References 8 Search Sort Most cited Newest Oldest Patent citations Title Any typearticle review book-chapter conference-paper preprint dissertation book dataset other Any fieldAgricultural and Biological Sciences Arts and Humanities Biochemistry, Genetics and Molecular Biology Business, Management and Accounting Chemical Engineering Chemistry Computer Science Decision Sciences Dentistry Earth and Planetary Sciences Economics, Econometrics and Finance Energy Engineering Environmental Science Health Professions Immunology and Microbiology Materials Science Mathematics Medicine Neuroscience Nursing Pharmacology, Toxicology and Pharmaceutics Physics and Astronomy Psychology Social Sciences Veterinary Open access Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy 2022 JAMA article Medicine Renal Diseases and Glomerulopathies Open access cited by 1 patent 360 citations Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial 2023 The Lancet article Medicine Renal Diseases and Glomerulopathies Open access 334 citations Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial 2023 The Lancet article Medicine Renal Diseases and Glomerulopathies Open access 305 citations After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy 2020 Kidney International article Medicine Renal Diseases and Glomerulopathies Open access cited by 2 patents 214 citations Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy 2020 Kidney International Reports article Medicine Renal Diseases and Glomerulopathies Open access cited by 18 patents 161 citations A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy 2024 Kidney International article Medicine Renal Diseases and Glomerulopathies Open access 137 citations Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy 2025 Kidney International article Medicine Renal Diseases and Glomerulopathies Open access cited by 1 patent 30 citations The humanistic burden of immunoglobulin A nephropathy on patients and care-partners in the United States 2024 Quality of Life Research article Medicine Renal Diseases and Glomerulopathies Open access 4 citations 8 results